ArticleBMJ open2021

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).

Kilian Eyerich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.